Stimwave LLC has received FDA 510(k) clearance for the first wireless, micro-technology neuromodulation device that can enable ongoing full-body MRI scans under certain scanning conditions for the relief of chronic peripheral nerve pain. Designed for people who suffer from severe intractable chronic pain, the StimQ Peripheral Nerve Stimulator (PNS) System offers an alternative for those who do not want to rely on invasive surgical procedures or ongoing opioid treatments. Stimwave LLC is headquartered in Pompano Beach, FL.
Indications: The device, which is less than 5% of the size of other standard implanted options, provides pain relief by delivering small pulses of energy in a fully-selectable manner to electrodes placed at a peripheral nerve enabling the brain to remap specific pain signals. The implant is powered by a small, flexible and comfortable wearable external unit.
Administration: The StimQ device can be used in a minimally-invasive, outpatient procedure for the treatment of various pain syndromes, including, but not limited to: shoulder pain, upper extremity neuropathy, mid and lower back pain, and lower extremity neuropathy. The recent FDA clearance enables the pain sufferer to have frequent and necessary MRI scans of any part of their body without removing the implant.
Stimwave receives FDA 510(k) clearance for the first full-body MRI scan ready wireless peripheral nerve stimulator (PNS) system. [news release]. Pompano Beach, Florida. August 9, 2017. http://www.pharmalive.com/stimwave-receives-fda-510k-clearance-for-the-f.... Accessed August 15, 2017.
This Week's Must Reads
Possible Link: Hepatic Steatosis and Brain Aging, JAMA Neurol; ePub 2017 Nov 20; Weinstein, et al
Neurologic Drug Shortages May Compromise Care, Neurology; ePub 2017 Nov 15; Omorodion, et al
Sleep Fragmentation Linked with PD in Older Adults, Mov Disord; ePub 2017 Oct 30; Sohail, Yu, et al
Dietary Sodium to Potassium Ratio and Stroke Risk, Stroke; ePub 2017 Oct 10; Willey, Gardener, et al
Sleep Apnea Did Not Accelerate Kidney Decline, Sleep; ePub 2017 Nov 3; Canales, Hagen, et al
Must Reads in FDA Actions
FDA Clears Apple Watch Heart Rate Accessory, PharmaLive news release; 2017 Nov 30
FDA Approves Oral Option for Pediatric Epilepsy, UCB news release; 2017 Nov 6
FDA Approves Soliris for Generalized MG, Alexion news release; 2017 Oct 23
FDA Approves Lyrica CR Extended-Release Tablets CV, Pfizer news release; 2017 Oct 12
FDA Approves New Treatment Option for Sleep Apnea, FDA news release; 2017 Oct 6